Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
Giannopoulos
Krzysztof
K
Dmoszyńska
Anna
A
Roliński
Jacek
J
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012074:Remission Induction; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects; D013792:Thalidomide / Q000008:administration & dosage*; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine